FSD Pharma Inc. | Finanzwire

BRIEF

published on 06/04/2024 at 13:35, 5 months 18 days ago

FSD Pharma Receives Institutional Review Board Approval for Unbuzzd(TM) Study

FSD Pharma Clinical Study Unbuzzd Alcohol Intoxication Institutional Review Board
PRESS RELEASE

published on 06/04/2024 at 13:30, 5 months 18 days ago

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma obtains IRB approval in the USA for the METAL-2 trial, allowing recruitment of clinical trial participants for alcohol intoxication research

FSD Pharma Clinical Study Alcohol Intoxication METAL-2 Trial IRB Approval
BRIEF

published on 05/31/2024 at 13:35, 5 months 22 days ago

FSD Pharma Wins Arbitration Award Against Former CEO Bokhari

Litigation FSD Pharma Biopharmaceutical Arbitration Awards Bokhari
PRESS RELEASE

published on 05/31/2024 at 13:30, 5 months 22 days ago

FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
FSD Pharma Inc. confirms arbitration awards against former CEO Dr. Raza Bokhari. United States District Court grants final judgment for monetary damages. Company focuses on biopharmaceutical solutions for neurodegenerative disorders

FSD Pharma Inc. Arbitration Awards Neurodegenerative Disorders United States District Court Biopharmaceutical Solutions
BRIEF

published on 05/28/2024 at 14:05, 5 months 25 days ago

FSD Pharma Submits Clinical Trial Protocol for Unbuzzd™ in Acute Alcohol Intoxication

FSD Pharma Clinical Trial Unbuzzd™ Alcohol Intoxication METAL-2 Trial
PRESS RELEASE

published on 05/28/2024 at 14:00, 5 months 25 days ago

FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma submits clinical trial protocol for Unbuzzd(TM) to assess safety and efficacy in a crossover design trial to study effects on alcohol intoxication. Dr. Andrzej Chruscinski comments on the milestone reached

FSD Pharma Unbuzzd(TM) Alcohol Intoxication Clinical Trial Protocol Dr. Andrzej Chruscinski
BRIEF

published on 05/24/2024 at 20:39, 5 months 29 days ago

FSD Pharma Announces Investor Relations Agreement with IR Agency LLC

Investor Relations FSD Pharma Biopharmaceutical IR Agency Lucid Psycheceuticals
PRESS RELEASE

published on 05/24/2024 at 20:34, 5 months 29 days ago

FSD Pharma Provides Corporate Update
FSD Pharma Inc. enters investor relations services agreement with IR Agency LLC, focusing on communicating information to the financial community. Company building innovative biotech solutions

Investor Relations FSD Pharma Inc. Biopharmaceutical Innovative Assets IR Agency LLC
BRIEF

published on 05/16/2024 at 14:05, 6 months 6 days ago

FSD Pharma Announces New Packaging for Unbuzzd™ Beverage

FSD Pharma Beverage Industry Unbuzzd New Packaging Responsible Drinking
PRESS RELEASE

published on 05/16/2024 at 14:00, 6 months 6 days ago

FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
FSD Pharma Inc. announces new packaging and logo for unbuzzd™ beverage product in collaboration with Celly Nutrition Corp. and Six+One, set to launch this summer, targeting alcohol metabolizing and promoting alertness

FSD Pharma Inc. Celly Nutrition Corp. Unbuzzd Six+One Packaging Logo

Published on 11/22/2024 at 23:55, 9 hours 20 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 45 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 10 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 10 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 45 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 15 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 15 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 21 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 19 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 15 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 40 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 13 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News